Mylan says Amgen's US court loss against Regeneron shows bundles rebates can be anticompetitive
MLex Summary: Mylan told a US federal judge that a recent decision against Amgen supports maintaining its claims against Sanofi-Aventis over an injectable form of the diabetes drug insulin glargine, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article